Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women (NCT07473310) | Clinical Trial Compass
RecruitingPhase 4
Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
Egypt70 participantsStarted 2025-11-11
Plain-language summary
The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women.
The main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of life, and whether these improvements are sustained over a 12-month follow-up period, compared with standard medical therapy.
Researchers will compare Li-SWT with oral solifenacin succinate, a commonly used antimuscarinic medication for OAB.
Participants will be randomly assigned to receive either Li-SWT once weekly for 8 weeks or solifenacin 5 mg taken orally once daily for 12 months. All participants will complete symptom questionnaires and three-day voiding diaries and will undergo uroflowmetry, post-void residual measurement, and filling cystometry at specified time points during follow-up.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* OAB symptoms persisting for ≥3 months.
* OAB Symptom Score (OABSS) ≥7.
* Ability and willingness to provide informed consent
Exclusion Criteria:
* Active urinary tract infection.
* Stress urinary incontinence as primary diagnosis.
* Pelvic organ prolapse stage ≥II.
* History of pelvic radiation or surgery within 6 months.
* Use of anticholinergics or β3-agonists for the past 4 weeks who are unwilling to undergo washout.
* Pregnancy or breast feeding.
* Neuropathic diseases or psychological disorders.
* History of urogenital malignancy.
* Uncontrolled DM (HbA1c \> 6.8)
* Uncorrected coagulopathy or severe cardiovascular disease.
* Contraindication to solifenacin e.g.: closed angle glaucoma)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in Overactive Bladder Symptom Score (OABSS) from baseline to different points of follow up